Neuroleptic malignant syndrome (NMS) is a rare but serious side effect of antipsychotic medications that are often prescribed to treat a wide variety of mental disorders. This syndrome, which is also sometimes called neuroleptic syndrome or malignant syndrome, affects the body's nervous system and can have severely debilitating neurological, physical, and psychological consequences. While the exact cause is not completely understood, NMS is often brought on by the sudden or excessive use of antipsychotic medications. Those who are at highest risk for developing NMS are individuals who have recently changed their dosage of antipsychotic drugs, those with pre-existing medical or neurological conditions, the elderly, and people with a family history of NMS. The most common symptoms of this disorder include muscular rigidity, elevated fever, autonomic dysfunction, tremor, and altered mental status. It is important to note that not all of these symptoms have to be present in order for a diagnosis to be made. Treatment for NMS includes stopping the antipsychotic medication that triggered the syndrome, treating symptoms with antipyretic agents and benzodiazepines, and providing supportive care, such as fluids, nutrition, and ventilation if necessary. In some cases, patients may require the use of other medications to reduce their muscle rigidity and manage their psychological symptoms. It is important to recognize the signs of NMS, as it can be life-threatening if left untreated. Anyone taking an antipsychotic medication should be aware of the risk associated with this disorder and seek medical attention immediately if any of the NMS symptoms arise. Early diagnosis and prompt treatment are the key to a complete recovery.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States